These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15535307)

  • 1. [Treatment of platinum-resistant ovarian cancer].
    Onishi Y; Nakamura T; Hatae M
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
    [No Abstract]   [Full Text] [Related]  

  • 2. [Second-line chemotherapy for recurrent ovarian cancer].
    Sugiyama T
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):28-32. PubMed ID: 15675578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
    Terauchi F; Hirano T; Taoka H; Masaki K; Yamamoto Y; Ogura H; Kubo H
    Int J Clin Oncol; 2003 Dec; 8(6):348-51. PubMed ID: 14663635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
    J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
    Sugiyama T; Yoshizaki A; Hatayama S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
    Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
    Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
    Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
    Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports.
    Kawaguchi M; Banno K; Susumu N; Yanokura M; Kuwabara Y; Hirao N; Tsukazaki K; Nozawa S
    Anticancer Res; 2005; 25(5):3547-51. PubMed ID: 16101178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New treatment strategy for stage III non-small-cell lung cancer].
    Yoh K; Kubota K
    Nihon Rinsho; 2002 May; 60 Suppl 5():485-9. PubMed ID: 12101719
    [No Abstract]   [Full Text] [Related]  

  • 14. Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
    Markman M
    J Exp Ther Oncol; 2004 Jul; 4(2):131-6. PubMed ID: 15500007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Nagourney RA
    Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
    Konishi H; Takehara K; Okame S; Yamamoto Y; Kojima A; Shiroyama Y; Yokoyama T; Nogawa T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1437-9. PubMed ID: 25434451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy for ovarian cancer--general review].
    Ochiai K
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():517-21. PubMed ID: 15535299
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
    Kim HS; Kang SB; Seo SS; Han SS; Kim JW; Park NH; Kang SB; Lee HP; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():627-34. PubMed ID: 19723113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New regimens for the treatment of gynecologic cancers].
    Sugiyama T; Ushijima K; Kamura T
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):375-81. PubMed ID: 10740630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.